🧬 Researchers at @wakeforestmed.bsky.social identified a protein that may help breast cancer spread to the brain and evade immune defenses. #bcsm #oncology

Read more ➡️: www.onclive.com/view/researc...

📰 The @fda.gov has granted priority review to elinzanetant for the treatment of moderate-to-severe vasomotor symptoms in patients receiving endocrine therapy for the management or prevention of HR+ breast cancer. #bcsm #oncology

Read more ➡️: www.onclive.com/view/fda-gra...

Dr. Karen van Baelen looked at modifiable risk factors in #ILC recurrence. Physical activity once again shown to be beneficial for #breastcancer patients! #ILCSymposium #lobmob #bcsm #exerciseismedicine

Guilford breaks down clinical management of hereditary diffuse #gastriccancer which is intense. Patients often have their stomachs removed, which comes w/ many adverse effects (& a few bennies, he noted, tongue firmly in cheek). #ILCSymposium #HDGC #lobmob #bcsm

Guilford proposes using the term hereditary diffuse gastric & #lobular #breastcancer syndrome for those w/ #CDH1 mutation since many people who survive #gastric #cancer will develop #lobularBC. #ILCSymposium @lobularbca.bsky.social @elbcc-2018.bsky.social #bcsm #lobmob

Keynote speaker Dr. Parry Guilford breaks down the similarities between #lobular #breastcancer and diffuse #gastriccancer via a hereditary #CDH1 mutation. #ILCSymposium. Good to know as we enter Hereditary Cancer Awareness Week! #bcsm @lobularbca.bsky.social

There's been "tremendous progress" in the creation of scientific models of #ILC for research -- always good for patients to hear! And more coming, per Dr. Adrien Lee. #ILCSymposium #BCSM @lobularbca.bsky.social @elbcc-2018.bsky.social @lobularbcuk.bsky.social

#Cancer researchers' favorite font, Comic Sans, rears its head at the #ILCSymposium. 😉 #CanSky #BCSM #funwithfonts

First up this morning, @fredhutch.org's translational researcher Dr. Kevin Cheung talking about the #metastatic "interactome" in #lobular #breastcancer #CanSky #ILCSymposium #bcsm @lobularbca.bsky.social @elbcc-2018.bsky.social @lobularbcuk.bsky.social

WATCH: @elmayermd.bsky.social, of @danafarber.bsky.social and @harvardmed.bsky.social, highlights the @fda.gov approval of camizestrant plus a CDK4/6 inhibitor for HR+, HER2–, emergent ESR1-mutated breast cancer. #bcsm #oncology

Read our coverage of the approval: www.onclive.com/view/fda-app...

WATCH 🎥: @elmayermd.bsky.social, of @danafarber.bsky.social and @harvardmed.bsky.social, discusses the @fda.gov approval of camizestrant for emergent ESR1-mutated breast cancer. #bcsm #oncology

Full video ➡️: www.onclive.com/view/dr-maye...

WATCH 🎥: Shimoli Barot, MD, of @clevelandclinic.bsky.social, discusses PATINA data showing improved PFS with palbociclib-based maintenance in HR-positive, HER2-positive metastatic breast cancer. #bcsm #oncology

Full video 👀: www.onclive.com/view/dr-baro...

WATCH 📺: Shimoli Barot, MD, of @clevelandclinic.bsky.social, considers how palbociclib-based maintenance could be sequenced with frontline T-DXd plus pertuzumab in HER2-positive metastatic breast cancer. #bcsm #oncology

Full video ➡️: www.onclive.com/view/dr-baro...

Great advocacy session this morning at the #ILCSymposium in San Francisco w/advocates from around the world. Here @clairehudson.bsky.social from @lobularbcuk.bsky.social talks about how to make it easier 4 #lobularBC patients to join #clinicaltrials. #CanSky #bcsm #lobmob

📰 At the 2026 International Invasive Lobular Carcinoma Symposium, @ucsfcancer.bsky.social clinicians and researchers will share their experiences and insights about future treatment directions. #bcsm #oncology

Read more ➡️: www.onclive.com/view/ucsf-br...

Great news regarding #LARC, Lobular America Research Consortium, a new research collaboration between 18 institutions across America, all digging into #nolump #lobular #breastxancer. Thank you @mjsikora.bsky.social and #racheljankowitz for leading this initiative! #CanSky #bcsm #ILCSymposium

The #ILCSymposium kicks off in San Francisco w/an advocate session led by @lobularbca.bsky.social advocates and Dr. Rita Mukhtar. #CanSky #bcsm #lobmob

FDA Flashback: ✨August 2026✨ in #BreastCancer
🔹 sNDA filed for gedatolisib in PIK3CA-mutant HR+/HER2– ABC
🔹 Fast track for PARG inhibitor ETX-19477 in BRCAm disease
🔹 2 giredestrant PDUFA dates ahead #bcsm #oncology

Learn more 🔎: www.onclive.com/view/fda-fla...

🇪🇺 @ema.europa.eu's CHMP recommended EU approval of adjuvant T-DXd monotherapy for patients with resected HER2+ breast cancer with residual invasive disease after neoadjuvant taxane-based and HER2-targeted therapy. #bcsm #oncology

Full details ➡️: www.onclive.com/view/chmp-re...

🏥Treatment of metastatic breast cancer is shifting in Japan.

Today, the MHLW approved first-line T-DXd plus pertuzumab for HER2+ breast cancer, as well as first-line Dato-DXd for TNBC #bcsm #oncology www.onclive.com/view/japan-a...